This was a cross-sectional, survey-based study of U.S. women aged 35 years and older. Researchers used an online questionnaire to assess symptoms, cycle changes, perceived menopausal status, and understanding of perimenopause. The analysis focused on how many women met criteria for perimenopause based on symptoms versus how many believed they were in perimenopause, and what factors drove this uncertainty. Primary endpoints were prevalence of perimenopause symptoms, self-reported menopausal status, and predictors of uncertainty.
Roughly one-third of women 35+ reported uncertainty about whether they were in perimenopause. Many women with symptom patterns consistent with perimenopause (cycle changes, hot flashes, sleep and mood changes) did not identify themselves as perimenopausal. Age strongly influenced self-labeling: women often assumed they were “too young” despite symptoms, while some older women assumed they were menopausal even without clear criteria. Health-care interactions and prior education about perimenopause were linked to better recognition, suggesting a knowledge and communication gap rather than absence of symptoms.
This was a cross-sectional survey, so it captures one moment in time and cannot prove cause-and-effect. Data were self-reported, which can introduce recall errors and misclassification of symptoms and cycle patterns. The online sample may not represent all racial, ethnic, socioeconomic, or medically underserved groups, limiting generalizability. Perimenopause was inferred from symptom and pattern criteria rather than confirmed with longitudinal hormone tracking, so some women may have been miscategorized.
The study highlights a large recognition gap: symptom-defined perimenopause often does not match women’s or clinicians’ labels. Methodological strengths include a sizable sample and focus on perceived status, but limitations of online, self-reported, cross-sectional data reduce certainty and generalizability. Findings fit with broader evidence that perimenopause is under-recognized, especially the earlier, irregular, symptom-heavy years. For restorative care, this supports earlier, structured assessment of cycle patterns, endocrine and metabolic context, and targeted education rather than waiting for 12 months without a period.
Encourage women in their mid-30s and beyond to track cycles, bleeding patterns, sleep, mood, energy, and vasomotor symptoms (hot flashes, night sweats). Clarify that perimenopause can start years before the final period and symptoms may come and go. Use cycle charts and symptom logs to guide root-cause evaluation: thyroid, prolactin, ovarian hormones, iron status, inflammation, and metabolic markers. Promote proactive visits when cycles shorten, become erratic, or bleeding changes significantly, especially when paired with mood, sleep, or cognitive shifts.
Perimenopause is the transition time before your periods fully stop, and it can start in your late 30s or 40s. This study found that many women with typical symptoms—cycle changes, heavy or light bleeding, hot flashes, sleep or mood changes—weren’t sure if they were in perimenopause. That uncertainty can delay getting support, especially if symptoms are blamed only on stress, aging, or mental health. Tracking your cycles and symptoms, then bringing that record to a clinician who understands hormones and root causes, can help you get clearer answers and more tailored care.
Consider structured perimenopause screening for women ≥35 with any of the following: cycle shortening/variability, new heavy or irregular bleeding, new-onset vasomotor symptoms, mid-sleep awakening, mood lability, or cognitive complaints. Integrate cycle charting with targeted labs: TSH/free T4, prolactin, CBC/ferritin, fasting glucose/insulin, lipids, hs-CRP, vitamin D, and, where helpful, follicular and mid-luteal estradiol and progesterone (or serial luteal P+E2 in restorative models). Educate that early perimenopause is often hormonally dynamic rather than simply “low estrogen,” and that symptoms may reflect fluctuations, anovulation, and interacting thyroid/metabolic factors. Use this evidence to normalize the transition, validate patient experience, and prioritize shared decision-making on lifestyle, nonhormonal options, and, when appropriate, individualized hormonal support rather than waiting for amenorrhea.
Educational insights, not a diagnosis or individualized treatment advice. Discuss findings with your own clinician. Visit Reproductive Health Insights to explore fertility resources.